Literature DB >> 21954985

Economic burden of chronic obstructive pulmonary disease.

W-S Kelvin Teo1, Woan-Shin Tan, Wai-Fung Chong, John Abisheganaden, Yii-Jen Lew, Tow-Keang Lim, Bee-Hoon Heng.   

Abstract

BACKGROUND AND
OBJECTIVE: The aim of this study was to estimate the direct medical costs of COPD in two public health clusters in Singapore from 2005 to 2009.
METHODS: Patients aged 40 years and over, who had been diagnosed with COPD, were identified in a Chronic Disease Management Data-mart. Annual utilization of health services in inpatient, specialist outpatient, emergency department and primary care settings was extracted from the Chronic Disease Management Data-mart. Trends in attributable costs, proportions of costs and health-care utilization were analyzed across each level of care. A weighted attribution approach was used to allocate costs to each health-care utilization episode, depending on the relevance of co-morbidities.
RESULTS: The mean total cost was approximately $9.9 million per year. Inpatient admissions were the major cost driver, contributing an average of $7.2 million per year. The proportion of hospitalization costs declined from 75% in 2005 to 68% in 2009. Based on the 5-year average, attendances at primary care clinics, emergency department and specialist clinics contributed 3%, 5% and 17%, respectively, of overall COPD costs. On average, 42% of the total cost burden was incurred for the medical management of COPD. The share of cost incurred for the treatment of conditions related and unrelated to COPD were 29% and 26%, respectively, of the total average costs.
CONCLUSIONS: COPD is likely to represent a significant burden to the public health system in most countries. The findings are particularly relevant to understanding the allocation of health-care resources and informing appropriate cost containment strategies.
© 2011 National Healthcare Group. Respirology © 2011 Asian Pacific Society of Respirology.

Entities:  

Mesh:

Year:  2012        PMID: 21954985     DOI: 10.1111/j.1440-1843.2011.02073.x

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  20 in total

1.  The Economic Effect of Early Management in Patients with Early Chronic Obstructive Pulmonary Disease: Results from a Population-Based Nationwide Survey.

Authors:  Young Seok Lee; Kyung Hoon Min; Chin Kook Rhee; Yong Hyun Kim; Seong Yong Lim; Soo-Jung Um; Chang-Hoon Lee; Ki-Suck Jung; Kwang Ha Yoo
Journal:  Lung       Date:  2019-03-11       Impact factor: 2.584

2.  Cost-effectiveness of indacaterol/glycopyrronium in comparison with salmeterol/fluticasone combination for patients with moderate-to-severe chronic obstructive pulmonary disease: a LANTERN population analysis from Singapore.

Authors:  Augustine Tee; Wai Leng Chow; Colin Burke; Basavarajaiah Guruprasad
Journal:  Singapore Med J       Date:  2018-03-16       Impact factor: 1.858

3.  Comparisons of Efficacy and Safety between Triple (Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting Beta-Agonist) Therapies in Chronic Obstructive Pulmonary Disease: Systematic Review and Bayesian Network Meta-Analysis.

Authors:  Hyun Woo Lee; Hyung Jun Kim; Eun Jin Jang; Chang-Hoon Lee
Journal:  Respiration       Date:  2021-05-10       Impact factor: 3.580

4.  Clinical factors affecting the direct cost of patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease.

Authors:  Tacettin Ornek; Meltem Tor; Remzi Altın; Figen Atalay; Elif Geredeli; Omer Soylu; Fatma Erboy
Journal:  Int J Med Sci       Date:  2012-06-05       Impact factor: 3.738

Review 5.  Managing comorbidities in COPD.

Authors:  Georgios Hillas; Fotis Perlikos; Ioanna Tsiligianni; Nikolaos Tzanakis
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-01-07

6.  A matched-group study protocol to evaluate the implementation of an Integrated Care Pathway programme for chronic obstructive pulmonary disease in Singapore.

Authors:  Christine Xia Wu; Woan Shin Tan; Ryan Chor Kian See; Weichang Yu; Lynette Siang Lim Kwek; Matthias Paul Han Sim Toh; Thong Gan Chee; Gerald Seng Wee Chua
Journal:  BMJ Open       Date:  2015-01-07       Impact factor: 2.692

Review 7.  Acute exacerbation of COPD: is it the "stroke of the lungs"?

Authors:  Georgios Hillas; Fotis Perlikos; Nikolaos Tzanakis
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-07-13

Review 8.  Genetic Polymorphism of Angiotensin-Converting Enzyme and Chronic Obstructive Pulmonary Disease Risk: An Updated Meta-Analysis.

Authors:  Sang Wook Kang; Su Kang Kim; Joo-Ho Chung; Hee-Jae Jung; Kwan-Il Kim; Jinju Kim; Ju Yeon Ban
Journal:  Biomed Res Int       Date:  2016-10-18       Impact factor: 3.411

9.  Disproportionate utilization of healthcare resources among veterans with COPD: a retrospective analysis of factors associated with COPD healthcare cost.

Authors:  Kyle Darnell; Alok Kumar Dwivedi; Zhouyang Weng; Ralph J Panos
Journal:  Cost Eff Resour Alloc       Date:  2013-06-13

10.  Study of Patients' Willingness to Pay for a Cure of Chronic Obstructive Pulmonary Disease in Taiwan.

Authors:  Yi-Ting Chen; Yung-Hsiang Ying; Koyin Chang; Ya-Hui Hsieh
Journal:  Int J Environ Res Public Health       Date:  2016-03-01       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.